Evidence map›Paper›PMID 41022592›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University

[Disrupting atherosclerotic plaque formation

Hongyang Wang, Wenyi Zhu, Xushen Chen, Tong Zhang, Zhiwei Cao, Jin Wang, Bo Xie, Qiang Liu, Xuefeng Ren

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongyang WangSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Wenyi ZhuSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xushen ChenSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Tong ZhangSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhiwei CaoZhejiang Chinese Medical University-Suzhou Chongsheng Medicine Joint Laboratory, Hangzhou 310053, China.
Jin WangZhejiang Chinese Medical University-Suzhou Chongsheng Medicine Joint Laboratory, Hangzhou 310053, China.
Bo XieZhejiang Chinese Medical University-Suzhou Chongsheng Medicine Joint Laboratory, Hangzhou 310053, China.
Qiang LiuZhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou 310053, China.
Xuefeng RenSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the molecular mechanism of

methodsApoE

resultsTreatment with JZHBD significantly reduced blood lipid and total bile acid levels, improved liver function and hepatic steatosis, and decreased aortic lipid deposition and plaque area in the mouse models of atherosclerosis. Transcriptomic analysis suggested that the therapeutic mechanism of JZHBD involved reverse cholesterol transport, PPAR signaling, and the inflammatory pathways. In atherosclerotic mice, JZHBD treatment obviously up-regulated hepatic expressions of PPARγ, LXRα, ABCA1, ABCG1, and CYP7A1, down-regulated hepatic expressions of p-p65/p65, IL-6, IL1β in the liver, increased ABCG5 and ABCG8 expressions in the intestines, and decreased ICAM-1 and VCAM-1 expressions in the aortic plaques.

conclusionsJZHBD improves atherosclerotic vascular damage and plaque formation possibly by regulating hepatic reverse cholesterol transport and inflammation

Indexed as

AtherosclerosisCholesterolDrugs, Chinese HerbalLiverPlaque, AtheroscleroticAnimalsBiological TransportDiet, High-FatMaleMiceMice, Inbred C57BLPPAR gammaCholesterolDrugs, Chinese HerbalPPAR gammaatherosclerosisJiangzhi Huaban Decoctionqi meridian-blood channelsreverse cholesterol transportvascular cell adhesion molecules

Identifiers

PMID41022592
PMCPMC12479261

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.